RAD-140 (Testolone) 10mg is a selective androgen receptor modulator (SARM) oral compound supplied in a 50 tablet pack. Manufactured for consistent potency, stability, and research applications.
Format50 Tablets
Concentration10mg
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
RAD-140, commonly known as Testolone, is a non steroidal SARM with one of the highest documented androgen receptor binding affinities in the SARM compound class, in some preclinical research models demonstrating receptor binding and anabolic activity comparable to or exceeding testosterone itself, while maintaining the tissue selective profile that distinguishes SARMs from traditional anabolic steroids. F40 Biotech’s formulation delivers 10mg per tablet in a 50 count format, consistent with the concentration most frequently referenced in RAD-140 preclinical research.
RAD-140’s research profile includes a distinctive characteristic not shared by LGD-4033, S23, or Ostarine within CSD’s SARM range, documented neuroprotective activity in preclinical models, with research examining its potential role in protecting against neurodegeneration through androgen receptor mediated mechanisms in neuronal tissue. This neuroprotective research dimension exists alongside its primary anabolic research applications and reflects RAD-140’s androgen receptor expression targeting extending into central nervous system tissue, distinguishing its research scope from SARMs whose documented activity remains confined to musculoskeletal tissue.
RAD-140’s high receptor binding affinity has also made it a frequently referenced compound in research examining the upper bounds of SARM mediated androgen receptor activation and the corresponding degree of HPG axis suppression. Comparative SARM research has positioned RAD-140 alongside S23 as among the more potent compounds in the class in terms of both anabolic signaling and endogenous testosterone suppression at equivalent research doses, contrasted against the comparatively milder suppression profile documented with Ostarine.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s RAD-140 meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside S23 and Ostarine in comparative SARM receptor binding affinity and HPG axis suppression studies. Browse CSD’s full SARM range for complete sourcing.
RAD-140 (Testolone) is a non steroidal selective androgen receptor modulator originally developed by Radius Health. One of the most potent SARMs in the research catalogue with a reported anabolic to androgenic ratio of approximately 90:1 compared to testosterone's 1:1. It has entered Phase I and Phase II clinical trials for breast cancer and muscle wasting research. RAD-140 is studied for lean mass accretion, strength enhancement, fat loss, and neuroprotective effects with strong anabolic activity in muscle and bone tissue and high tissue selectivity away from androgenic tissues such as the prostate. Its neuroprotective properties through androgen receptor activation in brain tissue are an increasingly active area of research.
RAD-140 occupies a distinct position in the SARM research catalogue, more potent than Ostarine but with greater tissue selectivity than LGD-4033. Compared to Ostarine, RAD-140 produces significantly stronger anabolic effects at equivalent doses with greater suppression. Compared to LGD-4033, RAD-140 produces comparable or superior anabolic effects with a reportedly higher anabolic to androgenic selectivity ratio. Though both produce significant HPG axis suppression requiring robust PCT. RAD-140 is additionally studied for neuroprotective applications not associated with LGD-4033 or Ostarine, making it a uniquely versatile SARM for researchers investigating both anabolic and neurological research applications.
RAD-140 has a half-life of approximately 15–20 hours, once daily administration is sufficient to maintain stable plasma Testolone levels throughout a research protocol. Morning administration is the most common research schedule. Common research doses range from 10–20mg daily; a single 10mg tablet covers the conservative starting dose, while two tablets deliver 20mg for more advanced protocols. The 50 tablet pack at 10mg provides 500mg total, sufficient for a complete 50 day research cycle at once daily 10mg dosing, or 25 days at 20mg daily.
Yes! RAD-140 produces significant dose dependent HPG axis suppression through androgen receptor activation. At standard research doses of 10–20mg daily, meaningful testosterone suppression occurs requiring a formal SERM based PCT protocol following the research cycle. A common PCT protocol following RAD-140 research uses Nolvadex 20–40mg daily for 4 weeks, optionally combined with Clomiphene 25–50mg daily for the first two weeks for additional FSH stimulation. Blood work before and after the research cycle is essential to assess individual suppression response and guide PCT decisions.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming concentration accuracy at 10mg per tablet and compound identity as RAD-140 (Testolone). A certificate of analysis is available.
